There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fulcrum Therapeutics (FULC – Research Report), Xeris Pharmaceuticals (XERS – Research Report) and Viking Therapeutics (VKTX – Research Report) with bullish sentiments.
Fulcrum Therapeutics (FULC)
In a report issued on May 16, Joseph Schwartz from SVB Securities reiterated a Buy rating on Fulcrum Therapeutics, with a price target of $8.00. The company’s shares closed last Friday at $3.25, close to its 52-week low of $2.25.
According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Fulcrum Therapeutics with a $7.00 average price target, representing a 109.0% upside. In a report issued on May 16, Oppenheimer also maintained a Buy rating on the stock with a $16.00 price target.
See today’s best-performing stocks on TipRanks >>
Xeris Pharmaceuticals (XERS)
SVB Securities analyst Roanna Ruiz reiterated a Buy rating on Xeris Pharmaceuticals on May 16 and set a price target of $5.00. The company’s shares closed last Friday at $2.90, close to its 52-week high of $3.03.
According to TipRanks.com, Ruiz is a 1-star analyst with an average return of
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $5.33, implying an 87.7% upside from current levels. In a report issued on May 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
Viking Therapeutics (VKTX)
In a report issued on May 16, Thomas Smith from SVB Securities maintained a Buy rating on Viking Therapeutics, with a price target of $28.00. The company’s shares closed last Friday at $22.97, close to its 52-week high of $25.03.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $32.78 average price target, which is a 40.8% upside from current levels. In a report issued on May 3, Roth MKM also maintained a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
- Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Announces CFO Resignation
- Fulcrum Therapeutics announces CFO resignation
